Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12776147 | 0.76 | GRM2 (0.38) | SIGMAR1TMEM97NPC1RAB9ANR1H2 | |
| SCHEMBL21914818 | 0.74 | AOC3 (0.58) | SIGMAR1AOC3TMEM97NPC1RAB9A | |
| SCHEMBL9368116 | 0.73 | NPC1 (0.67) | NPC1RAB9ANR1H2NR1H3KDM4C | |
| SCHEMBL12776143 | 0.72 | KDM4E (0.38) | SIGMAR1AOC3TMEM97NPC1RAB9A | |
| SCHEMBL27217295 | 0.71 | KDM4C (0.43) | NPC1RAB9ANR1H2NR1H3KDM4C | |
| SCHEMBL23447248 | 0.71 | SIGMAR1 (0.38) | SIGMAR1AOC3TMEM97KDM4C | |
| SCHEMBL23130722 | 0.70 | SMN1; SMN2 (0.46) | NPC1RAB9ANR1H2NR1H3KDM4C | |
| SCHEMBL12776157 | 0.70 | NPC1 (0.46) | SIGMAR1TMEM97NPC1RAB9AKDM4C | |
| SCHEMBL12343973 | 0.68 | NR1H3 (0.59) | SIGMAR1TMEM97NPC1RAB9ANR1H2 | |
| SCHEMBL17803263 | 0.68 | SIGMAR1 (0.65) | SIGMAR1AOC3TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | SIGMAR1 4080/4885AOC3 2447/4885TMEM97 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.